SinoMab BioScience (HKG:3681) booked 105 million yuan in attributable loss for 2025, narrowing from 185.1 million yuan in 2024, according to a Hong Kong bourse filing Monday.
Shares of the firm gained over 1% in morning trade Tuesday.
Loss per share was 0.09 yuan, compared with 0.17 yuan in the prior year.
The company did not generate any revenue during the year. SinoMab recorded 2 million yuan in sales for 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.